The effect of
immunotherapy in cancer therapeutics has been identified beforehand via the
induction of infection on tumour regression. Coley showed that streptococcus
inoculation resulted in the shrinkage of soft-tissue tumors, such as sarcomas.
However, results were not verified towards research progress.
Paul Ehrlich
presented of increased significance that the augmented
immune response attacks tumor cells, while tumor cells deceive the immune
system promoting tumor growth.
For example,
interferon- α and interleukin-2, have been administrated in advanced melanoma
and renal cell carcinoma. Evidence of durable responses in a small proportion
of treated patients there exists, suggesting the potential for long-term use
with view to survival.
No comments:
Post a Comment